Molly Bartlett
Annapolis, MDNPI 1326042094
Payments from drug & device makers
Across 73 payments — averaging $32.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$665
- Sumitomo Pharma America, Inc.$325
- Astellas Pharma US Inc$248
- Myovant Sciences Inc.$138
- AbbVie$124
- AstraZeneca$118
- plus $788 from 18 others
What the payments were for
- Travel & lodging$1818%
- Food & beverage$2,22492%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 9 | $665 |
| Sumitomo Pharma America, Inc. | 13 | $325 |
| Astellas Pharma US Inc | 12 | $248 |
| Myovant Sciences Inc. | 3 | $138 |
| AbbVie | 6 | $124 |
| AstraZeneca | 1 | $118 |
| Bayer | 2 | $106 |
| Shield Therapeutics Inc | 1 | $84 |
| Boston Scientific | 3 | $82 |
| Tolmar Pharmaceuticals, Inc. | 3 | $72 |
| Accord Healthcare, Inc. | 3 | $63 |
| 180 Medical, Inc. | 2 | $56 |
| Dendreon Pharmaceuticals LLC | 2 | $48 |
| Ferring Pharmaceuticals Inc. | 2 | $46 |
| Olympus America Inc. | 2 | $32 |
| Tempus AI, Inc | 1 | $30 |
| Progenics Pharmaceuticals, Inc. | 1 | $26 |
| Urogen Pharma, Inc. | 1 | $25 |
| Urovant Sciences Inc | 1 | $24 |
| Antares Pharma, Inc. | 1 | $24 |
| Novo Nordisk | 1 | $23 |
| Merck | 1 | $18 |
| Endo Pharmaceuticals Inc. | 1 | $16 |
| Vertex | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$346
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 79 | $77,831 |
| MyrbetriqMirabegron | 34 | $38,476 |
| Fosfomycin Tromethamine | 19 | $5,239 |
| Potassium Citrate ErPotassium Citrate | 37 | $4,433 |
| Tamsulosin Hcl | 132 | $3,070 |
| Estradiol | 39 | $3,002 |
| Trospium Chloride ErTrospium Chloride | 14 | $2,690 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 39 | $1,271 |
| Cephalexin | 43 | $1,112 |
| CefuroximeCefuroxime Axetil | 54 | $1,022 |
| NitrofurantoinNitrofurantoin Macrocrystal | 18 | $966 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 56 | $829 |
| Solifenacin Succinate | 13 | $738 |
| Finasteride | 37 | $691 |
| Silodosin | 15 | $548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $325 | $77,83179 claims |
| Astellas Pharma US IncMyrbetriq | $248 | $38,47634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Marylandon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.